Nuo Therapeutics, Inc.
AURX
$1.63
$0.00460.28%
OTC PK
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 91.94% | 106.48% | 100.46% | 59.78% | 208.63% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 91.94% | 106.48% | 100.46% | 59.78% | 208.63% |
Cost of Revenue | 144.10% | 139.13% | 108.70% | 86.80% | 218.54% |
Gross Profit | 80.66% | 97.50% | 98.26% | 51.57% | 206.45% |
SG&A Expenses | 41.78% | 24.10% | 16.08% | -12.42% | -13.18% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 49.12% | 30.27% | 20.61% | -7.19% | -8.37% |
Operating Income | -20.30% | -5.06% | 3.51% | 26.87% | 37.80% |
Income Before Tax | -20.29% | -5.26% | 23.96% | 26.87% | 38.05% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -20.29% | -5.26% | 23.96% | 26.87% | 38.05% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -20.29% | -5.26% | 23.96% | 26.87% | 38.05% |
EBIT | -20.30% | -5.06% | 3.51% | 26.87% | 37.80% |
EBITDA | -16.87% | -3.44% | 4.72% | 27.04% | 37.97% |
EPS Basic | -14.88% | 0.63% | 31.37% | 32.45% | 42.11% |
Normalized Basic EPS | -14.47% | 0.00% | 12.50% | 32.48% | 41.54% |
EPS Diluted | -14.88% | 0.63% | 31.37% | 32.45% | 42.11% |
Normalized Diluted EPS | -14.47% | 0.00% | 12.50% | 32.48% | 41.54% |
Average Basic Shares Outstanding | 4.85% | 5.82% | 10.83% | 8.24% | 6.84% |
Average Diluted Shares Outstanding | 4.85% | 5.82% | 10.83% | 8.24% | 6.84% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |